{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T03:12:37Z","timestamp":1793157157978,"version":"4.5.0"},"reference-count":27,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>The major toxic effect of hydroxychloroquine is retinopathy. Thus, current guidelines recommend limiting the dose and screening annually for retinopathy among all long-term users, but individual patient factors may be associated with retinopathy risk.<\/jats:p><\/jats:sec>Objective<\/jats:title>To identify risk factors beyond hydroxychloroquine dose and duration of use for hydroxychloroquine retinopathy.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This cohort study of 4677 patients in the Kaiser Permanente Northern California integrated health network who initiated hydroxychloroquine, continued treatment, and underwent retinopathy screening after 5 years of use was conducted from July 1, 1997, to December 31, 2020, with up to 15 years of follow-up. Statistical analysis was performed in August 2023.<\/jats:p><\/jats:sec>Exposure<\/jats:title>Candidate risk factors included age at hydroxychloroquine initiation, sex, race and ethnicity, indications, chronic kidney disease (CKD), liver disease, diabetes, tamoxifen use, and medications that interact with hydroxychloroquine metabolism. Hydroxychloroquine dose was assessed from pharmacy dispensing records.<\/jats:p><\/jats:sec>Main Outcome and Measures<\/jats:title>Incident hydroxychloroquine retinopathy was adjudicated from masked review of guideline-recommended screening studies and classified as parafoveal or pericentral pattern. Multivariable Cox proportional hazards regression was used to assess potential risk factors for hydroxychloroquine retinopathy within 15 years of initiation.<\/jats:p><\/jats:sec>Results<\/jats:title>Of 4677 long-term hydroxychloroquine users (mean [SD] age at initiation, 52.4 [14.1] years; 3877 women [82.9%]), 125 patients developed hydroxychloroquine retinopathy within 15 years (102 parafoveal, 23 pericentral). Older age at time of hydroxychloroquine initiation was associated with retinopathy risk, with adjusted hazard ratios (HRs) of 2.48 (95% CI, 1.28-4.78) for those aged 45 to 54 years, 3.82 (95% CI, 2.05-7.14) for those aged 55 to 64 years, and 5.68 (95% CI, 2.99-10.79) for those aged 65 years or older compared with those younger than 45 years. The risk of retinopathy was higher among females than males (HR, 3.83 [95% CI, 1.86-7.89]), among patients with CKD stage 3 or greater (HR, 1.95 [95% CI, 1.25-3.04]), and among individuals with tamoxifen use (HR, 3.43 [95% CI, 1.08-10.89]). The likelihood of pericentral retinopathy was higher among Asian patients (HR, 15.02 [95% CI, 4.82-46.87]) and Black patients (HR, 5.51 [95% CI, 1.22-24.97]) compared with non-Hispanic White patients.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>This study suggests that increasing age, female sex, CKD stage 3 or greater, and tamoxifen use were associated with a higher risk of hydroxychloroquine retinopathy, whereas being younger than 45 years at hydroxychloroquine initiation and male sex were associated with a lower risk. Race and ethnicity were also associated with the pattern of retinopathy. These factors should be incorporated into hydroxychloroquine dosing decisions.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2024.10677","type":"journal-article","created":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T15:01:08Z","timestamp":1715266868000},"page":"e2410677","source":"Crossref","is-referenced-by-count":50,"title":["Risk Factors for Hydroxychloroquine Retinopathy and Its Subtypes"],"prefix":"10.1001","volume":"7","author":[{"given":"April M.","family":"Jorge","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald B.","family":"Melles","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Kaiser Permanente Northern California, Oakland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael F.","family":"Marmor","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Stanford University School of Medicine, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baijun","family":"Zhou","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqing","family":"Zhang","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyon K.","family":"Choi","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2024,5,9]]},"reference":[{"issue":"9","key":"zoi240382r1","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1038\/nrrheum.2012.106","article-title":"New insights into mechanisms of therapeutic effects of antimalarial agents in SLE.","volume":"8","author":"Wallace","year":"2012","journal-title":"Nat Rev Rheumatol"},{"issue":"9","key":"zoi240382r2","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1177\/0961203306071872","article-title":"Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus.","volume":"15","author":"Ruiz-Irastorza","year":"2006","journal-title":"Lupus"},{"issue":"8","key":"zoi240382r3","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1002\/acr.v73.8","article-title":"Hydroxychloroquine and mortality among patients with systemic lupus erythematosus in the general population.","volume":"73","author":"Jorge","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"12","key":"zoi240382r4","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s41584-018-0111-8","article-title":"Hydroxychloroquine retinopathy\u2014implications of research advances for rheumatology care.","volume":"14","author":"Jorge","year":"2018","journal-title":"Nat Rev Rheumatol"},{"issue":"2","key":"zoi240382r5","doi-asserted-by":"publisher","first-page":"166","DOI":"10.7326\/M22-2453","article-title":"Hydroxychloroquine dose and risk for incident retinopathy: a cohort study.","volume":"176","author":"Melles","year":"2023","journal-title":"Ann Intern Med"},{"issue":"12","key":"zoi240382r6","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1001\/jamaophthalmol.2014.3459","article-title":"The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy.","volume":"132","author":"Melles","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"zoi240382r7","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab844","article-title":"Risk of hydroxychloroquine retinopathy in the community.","author":"Dabit","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"zoi240382r8","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1002\/acr.v62:6","article-title":"Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus.","volume":"62","author":"Wolfe","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"3","key":"zoi240382r9","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1002\/art.v72.3","article-title":"Hydroxychloroquine blood levels predict hydroxychloroquine retinopathy.","volume":"72","author":"Petri","year":"2020","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"zoi240382r10","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1016\/j.ophtha.2015.01.014","article-title":"Pericentral hydroxychloroquine retinopathy in Korean patients.","volume":"122","author":"Lee","year":"2015","journal-title":"Ophthalmology"},{"issue":"3","key":"zoi240382r11","doi-asserted-by":"publisher","first-page":"522","DOI":"10.3346\/jkms.2017.32.3.522","article-title":"Frequency and clinical characteristics of hydroxychloroquine retinopathy in Korean patients with rheumatologic diseases.","volume":"32","author":"Eo","year":"2017","journal-title":"J Korean Med Sci"},{"key":"zoi240382r12","doi-asserted-by":"publisher","first-page":"811","DOI":"10.2147\/OPTH","article-title":"Somatotype, the risk of hydroxychloroquine retinopathy, and safe daily dosing guidelines.","volume":"12","author":"Browning","year":"2018","journal-title":"Clin Ophthalmol"},{"issue":"1","key":"zoi240382r13","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.ophtha.2014.07.018","article-title":"Pericentral retinopathy and racial differences in hydroxychloroquine toxicity.","volume":"122","author":"Melles","year":"2015","journal-title":"Ophthalmology"},{"issue":"6","key":"zoi240382r14","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1111\/bcp.1989.27.issue-6","article-title":"Bioavailability of hydroxychloroquine tablets in healthy volunteers.","volume":"27","author":"Tett","year":"1989","journal-title":"Br J Clin Pharmacol"},{"issue":"14","key":"zoi240382r15","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.2174\/1389200221999201208211537","article-title":"Metabolism and interactions of chloroquine and hydroxychloroquine with human cytochrome P450 enzymes and drug transporters.","volume":"21","author":"Rendic","year":"2020","journal-title":"Curr Drug Metab"},{"issue":"3","key":"zoi240382r16","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41584-020-0372-x","article-title":"Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology.","volume":"16","author":"Schrezenmeier","year":"2020","journal-title":"Nat Rev Rheumatol"},{"issue":"6","key":"zoi240382r17","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/j.ophtha.2016.01.058","article-title":"Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision).","volume":"123","author":"Marmor","year":"2016","journal-title":"Ophthalmology"},{"issue":"12","key":"zoi240382r18","doi-asserted-by":"publisher","first-page":"3807","DOI":"10.1093\/rheumatology\/keaa157","article-title":"Risk factors for hydroxychloroquine retinopathy in systemic lupus erythematosus: a case-control study with hydroxychloroquine blood-level analysis.","volume":"59","author":"Lenfant","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"zoi240382r19","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13293-021-00401-3","article-title":"The roles of sex and gender in women\u2019s eye health disparities in the United States.","volume":"12","author":"Aninye","year":"2021","journal-title":"Biol Sex Differ"},{"issue":"3","key":"zoi240382r20","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1111\/aos.2017.95.issue-3","article-title":"Macular thickness in healthy eyes of adults (N = 4508) and relation to sex, age and refraction: the Troms\u00f8 Eye Study (2007-2008).","volume":"95","author":"von Hanno","year":"2017","journal-title":"Acta Ophthalmol"},{"key":"zoi240382r21","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1177\/0961203396005001041","article-title":"Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases.","volume":"5","author":"Furst","year":"1996","journal-title":"Lupus"},{"issue":"1","key":"zoi240382r22","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12920-022-01171-6","article-title":"Relationship of cytochrome P450 gene polymorphisms with blood concentrations of hydroxychloroquine and its metabolites and adverse drug reactions.","volume":"15","author":"Gao","year":"2022","journal-title":"BMC Med Genomics"},{"issue":"1","key":"zoi240382r23","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1002\/art.v68.1","article-title":"Association of polymorphisms of cytochrome P450 2D6 with blood hydroxychloroquine levels in patients with systemic lupus erythematosus.","volume":"68","author":"Lee","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"zoi240382r24","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1080\/13816810.2020.1747093","article-title":"Genetic susceptibility to hydroxychloroquine retinal toxicity.","volume":"41","author":"Mack","year":"2020","journal-title":"Ophthalmic Genet"},{"issue":"2","key":"zoi240382r25","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.semarthrit.2018.01.002","article-title":"Dynamic patterns and predictors of hydroxychloroquine nonadherence among Medicaid beneficiaries with systemic lupus erythematosus.","volume":"48","author":"Feldman","year":"2018","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"zoi240382r26","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.rdc.2020.09.004","article-title":"Disparities in lupus and lupus nephritis care and outcomes among US Medicaid beneficiaries.","volume":"47","author":"Pryor","year":"2021","journal-title":"Rheum Dis Clin North Am"},{"issue":"11","key":"zoi240382r27","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1002\/acr.2018.70.issue-11","article-title":"Baseline retinal examinations in patients with systemic lupus erythematosus newly initiating hydroxychloroquine treatment in a US Medicaid systemic lupus erythematosus population, 2000-2010.","volume":"70","author":"Lin","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2818491\/jorge_2024_oi_240382_1714571182.88628.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T15:01:14Z","timestamp":1715266874000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2818491"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,9]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.10677","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,9]]}}}